Abstract

To evaluate whether preventive treatment can modify endothelial and oxidative biomarkers of vascular disease risk in patients with high-frequency episodic and chronic migraine. In this observational, prospective pilot study, 88 prophylactic treatment-naïve patients with episodic and chronic migraine and 56 healthy sex/age matched controls underwent ultrasonography exams and blood tests at baseline, and again in the migraine patients after 3 months’ treatment with metoprolol or topiramate. Biomarkers for endothelial function and oxidative stress were analyzed. At baseline, patients with migraine in the low-frequency episodic group had differences exclusively in nitrates 17.6 versus 27.33 µM; p = 0.046 compared to the controls. However, when comparing the group comprised of patients with high-frequency episodic migraine and chronic migraine versus controls, statistically significant differences appeared in hsCRP 2.68 versus 1.64 mg/dL; p = 0.049, vWF antigen (133% vs. 110%; p = 0.020, vWF activity (111% vs. 90%; p = 0.010) and isoprostane levels (181 vs. 238 µM; p = 0.05). Only in the chronic migraine subgroup did we found statistically significant differences in CIMT (0.60 vs. 0.54 mm; p = 0.042) which were significantly greater than in the controls. After treatment, patients who respond to preventive treatment exhibited significantly higher levels of nitrates (24.2–13.8 µM; p = 0.022) and nitrites (10.4–3.43 µM; p = 0.002) compared than non-responders. Moreover, biomarker levels improved in treatment-responsive patients with migraine; hsCRP levels decreased from 2.54 to 1.69 mg/dL (p < 0.05), vWF activity levels decreased from 124 to 103 IU/dL (p = 0.003) and prothrombin activity decreased from 1.01 to 0.93 (p = 0.01). These differences were also observed in the high-frequency and chronic migraine subgroup and reach statistical significance in the case of hsCRP, which decreased from 2.12 to 0.83 mg/dL (p = 0.048). Patients with migraines have differences in biomarker levels compared to controls, suggesting endothelial and oxidative dysfunction. The greatest differences in biomarker levels compared to controls are observed in migraine patients in the high-frequency and chronic migraine subgroups. Based on our results, preventive treatment is capable of modifying markers of endothelial dysfunction and oxidative stress in migraine patients, even in cases of chronic and high-frequency migraine.

Details

Title
Prophylactic treatment can modify vascular risk biomarkers in high-frequency episodic and chronic migraine patients: a pilot study
Author
González Mingot, Cristina 1   VIAFID ORCID Logo  ; Santos Lasaosa, Sonia 2   VIAFID ORCID Logo  ; Colàs Campàs, Laura 3   VIAFID ORCID Logo  ; Chilangua Canaval, Laura 4   VIAFID ORCID Logo  ; Gil Sánchez, Anna 5   VIAFID ORCID Logo  ; Brieva Ruiz, Luis 1   VIAFID ORCID Logo  ; Marzo Alonso, María Cristina 6   VIAFID ORCID Logo  ; Peralta Moncusi, Silvia 5   VIAFID ORCID Logo  ; Valls Marsal, Joan 3   VIAFID ORCID Logo  ; Cambray Carner, Serafí 3   VIAFID ORCID Logo  ; Purroy García, Francisco 7   VIAFID ORCID Logo 

 University of Lleida (UdL)-IRBLleida, Neuroimmunology Group, Department of Medicine, Lleida, Spain (GRID:grid.15043.33) (ISNI:0000 0001 2163 1432); Neurology Service of Hospital Arnau de Vilanova of Lleida, Lleida, Spain (GRID:grid.411443.7) (ISNI:0000 0004 1765 7340) 
 Neurology Service of Hospital Clínico Lozano Blesa of Zaragoza, Zaragoza, Spain (GRID:grid.411050.1) (ISNI:0000 0004 1767 4212) 
 Biomedical Research Institute of Lleida, Lleida, Spain (GRID:grid.420395.9) (ISNI:0000 0004 0425 020X) 
 Neurology Service of Hospital Son Espases, Palma, Spain (GRID:grid.411164.7) (ISNI:0000 0004 1796 5984) 
 University of Lleida (UdL)-IRBLleida, Neuroimmunology Group, Department of Medicine, Lleida, Spain (GRID:grid.15043.33) (ISNI:0000 0001 2163 1432) 
 Hematology Service of Hospital Arnau de Vilanova of Lleida, Lleida, Spain (GRID:grid.411443.7) (ISNI:0000 0004 1765 7340) 
 Neurology Service of Hospital Arnau de Vilanova of Lleida, Lleida, Spain (GRID:grid.411443.7) (ISNI:0000 0004 1765 7340) 
Pages
19416
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2887159066
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.